A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection

NCT05861674 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

101

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis Delta Virus Infection

Interventions

BIOLOGICAL: HH-003(20mg/kg)
BIOLOGICAL: HH-003(10mg/kg)
DRUG: TAF

Sponsor

Huahui Health